Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases.
Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases.
复制标题
DOI：
10.1080/02770903.2021.2020815
复制
发表时间：
2022-12
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
确定在过敏性和非过敏性气道炎症疾病中重要的IL-33免疫生物学的关键特征以及减轻疾病负担的潜在治疗策略。从2021年3月至2021年12月，我们对PubMed或BioMed Explorer进行了系统、重点的文献检索，检索关键词包括IL-33/ST2、遗传多态性、转录、翻译、翻译后修饰、核蛋白、过敏、哮喘和肺病。IL-33的临床试验信息于2021年8月从clinicaltrials.gov上提取。总共有72篇与IL-33免疫生物学和/或临床肺部疾病相关的出版物被确定（过敏性气道炎症/过敏性哮喘n = 26，非过敏性气道炎症n = 9, COPD n = 8，肺纤维化n = 10）。炎症性肺病患者血清、BALF和/或肺部IL-33水平较高。8项研究描述了病毒感染和IL-33, 4项研究与COVID-19相关。机制研究（n = 39），包括与IL-33免疫生物学相关的转录物变异和翻译后修饰。9项研究描述了IL-33或ST2的单核苷酸多态性（哮喘n = 5，炎症性肠病n = 1，蕈样真菌病n = 1，强直性脊柱炎n = 1，冠状动脉疾病n = 1）。Clinicaltrials.gov网站上的搜索结果显示，84项研究中有17项与肺部疾病的治疗或生物标志物相关。IL-33在变应性和非变应性气道炎症的发病机制中起着不可或缺的作用，一些新兴的临床试验研究了治疗方法。目前的数据支持IL-33在肺损伤信号传导、修复和再生中的关键作用。
Identify key features of IL-33 immunobiology important in allergic and nonallergic airway inflammatory diseases and potential therapeutic strategies to reduce disease burden. PubMed, clinicaltrials.gov A systematic and focused literature search was conducted of PubMed from March 2021 to December 2021 using keywords to either PubMed or BioMed Explorer including IL-33/ST2, genetic polymorphisms, transcription, translation, post-translation modification, nuclear protein, allergy, asthma, and lung disease. Clinical trial information on IL-33 was extracted from clinicaltrials.gov in August 2021. In total, 72 publications with relevance to IL-33 immunobiology and/or clinical lung disease were identified (allergic airway inflammation/allergic asthma n = 26, non-allergic airway inflammation n = 9, COPD n = 8, lung fibrosis n = 10). IL-33 levels were higher in serum, BALF and/or lungs across inflammatory lung diseases. Eight studies described viral infections and IL-33 and 4 studies related to COVID-19. Mechanistic studies (n = 39) including transcript variants and post-translational modifications related to the immunobiology of IL-33. Single nucleotide polymorphism in IL-33 or ST2 were described in 9 studies (asthma n = 5, inflammatory bowel disease n = 1, mycosis fungoides n = 1, ankylosing spondylitis n = 1, coronary artery disease n = 1). Clinicaltrials.gov search yielded 84 studies of which 17 were related to therapeutic or biomarker relevance in lung disease. An integral role of IL-33 in the pathogenesis of allergic and nonallergic airway inflammatory disease is evident with several emerging clinical trials investigating therapeutic approaches. Current data support a critical role of IL-33 in damage signaling, repair and regeneration of lungs.
登录
查看更多内容
DOI：
10.2147/dmso.s251978
发表时间：
2020
期刊：
Diabetes, metabolic syndrome and obesity : targets and therapy
影响因子：
--
作者：
Hasan A;Kochumon S;Al-Ozairi E;Tuomilehto J;Al-Mulla F;Ahmad R
通讯作者：
Ahmad R
影响因子：
4.6
作者：
Gatti F;Mia S;Hammarström C;Frerker N;Fosby B;Wang J;Pietka W;Sundnes O;Hol J;Kasprzycka M;Haraldsen G
通讯作者：
Haraldsen G
影响因子：
2.7
作者：
Hayakawa H;Hayakawa M;Tominaga SI
通讯作者：
Tominaga SI
影响因子：
24.1
作者：
通讯作者：
--
影响因子：
4.4
作者：
Fu, Zhirong;Thorpe, Michael;Hellman, Lars
通讯作者：
Hellman, Lars